Teixeira Suzana C, Rebolleda José Ferrér, Koolen Bas B, Wesseling Jelle, Jurado Raúl Sánchez, Stokkel Marcel P M, Del Puig Cózar Santiago María, van der Noort Vincent, Rutgers Emiel J Th, Valdés Olmos Renato A
1 Nuclear Medicine Department, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
2 Surgery Department, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
AJR Am J Roentgenol. 2016 Jun;206(6):1307-14. doi: 10.2214/AJR.15.15371. Epub 2016 Apr 8.
The purposes of this study were to evaluate the performance of a mammography with molecular imaging PET (MAMMI-PET) system for breast imaging in the hanging-breast position for the visualization of primary breast cancer lesions and to compare this method with whole-body PET/CT.
Between March 2011 and March 2014, a prospective evaluation included women with one or more histologically confirmed primary breast cancer lesions (index lesions). After injection of 180-240 MBq of (18)F-FDG, whole-body PET/CT and MAMMI-PET acquisitions were performed, index lesions were scored 0, 1, or 2 for FDG uptake relative to background. Detection and FDG uptake were compared by breast length, maximal tumor diameter, affected breast quadrants, tumor grade, and histologic and immunologic sub-types. Finally, the two PET modalities were compared for detection of index lesions.
For 234 index lesions (diameter, 5-170 mm), the overall sensitivity was 88.9% for MAMMI-PET and 91% for PET/CT (p = 0.61). Twenty-three (9.8%) index lesions located too close to the pectoral muscle were missed with MAMMI-PET, and 20 index lesions were missed with PET/CT. Lesion visibility on MAMMI-PET images was influenced by tumor grade (p = 0.034) but not by cancer subtype (p = 0.65).
Although in an overall evaluation MAMMI-PET was not superior to PET/CT, MAMMI-PET does have higher sensitivity for primary breast cancer lesions within the scanning range of the device. Optimization of the positioning device may increase visualization of the most dorsal lesions.
本研究旨在评估乳腺钼靶与分子影像PET(MAMMI-PET)系统在乳房下垂位用于乳腺成像以显示原发性乳腺癌病灶的性能,并将该方法与全身PET/CT进行比较。
2011年3月至2014年3月期间,一项前瞻性评估纳入了患有一个或多个经组织学确诊的原发性乳腺癌病灶(索引病灶)的女性。注射180-240MBq的(18)F-FDG后,进行全身PET/CT和MAMMI-PET采集,根据相对于背景的FDG摄取情况将索引病灶评分为0、1或2。通过乳房长度、最大肿瘤直径、患侧乳腺象限、肿瘤分级以及组织学和免疫亚型比较检测情况和FDG摄取情况。最后,比较两种PET模式对索引病灶的检测情况。
对于234个索引病灶(直径5-170mm),MAMMI-PET的总体灵敏度为88.9%,PET/CT为91%(p=0.61)。MAMMI-PET漏诊了23个(9.8%)距离胸肌过近的索引病灶,PET/CT漏诊了20个索引病灶。MAMMI-PET图像上病灶的可见性受肿瘤分级影响(p=0.034),但不受癌症亚型影响(p=0.65)。
尽管总体评估中MAMMI-PET并不优于PET/CT,但MAMMI-PET对设备扫描范围内的原发性乳腺癌病灶具有更高的灵敏度。优化定位装置可能会增加最靠背部病灶的可视性。